Press Release
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m.
Press Release
atai Life Sciences to Participate in Upcoming March Investor Conferences
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conferences in March: Citi Winter Biotech
Press Release
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
- Leading non-profit and commercial organizations in psychedelic science united in visions to heal mental health conditions - Donation is from atai Impact, the philanthropic arm of mental health company, atai Life Sciences - Funds will help support the general operations of MAPS, including its
Press Release
atai Life Sciences to Participate in Upcoming February Investor Conference
NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming investor conference in February.
Press Release
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets
Press Release
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
•  Enables expansion of PCN-101 clinical development to the U.S. •  atai plans to initiate clinical drug-drug interaction (DDI) study in early 2022 to assess pharmacokinetics of PCN-101 when used concurrently with other drugs •  DDI trial will complement existing Phase 2a trial in
Displaying 13 - 18 of 67